The company said it took financial hits from the Inflation Reduction Act's Medicare Part D redesign, which included higher ...

Researchers at AACR's annual meeting said they hope the vaccine will show stronger efficacy in patients with minimal residual disease.

In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.

Soriot discussed the impact of potential tariffs during a call on AstraZeneca's earnings. For the three months ended March 31, during which period the firm netted $13.59 billion in total revenue, an ...

Both gene therapies were approved as treatments for dystrophic epidermolysis bullosa, a rare and debilitating genetic skin condition.

During an earnings call, the firm reported strong sales for Pluvicto and other precision medicines and elaborated on its US manufacturing plans.

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

In the study, patients with advanced solid tumors must be HLA-A*02:01 positive and harbor a p53 R175H mutation.

The RAS(ON) inhibitor shrunk tumors in around 60 percent of patients with KRAS G12D mutations, according to a study presented at AACR's annual meeting.

The model combines estimates of skeletal muscle with routinely collected clinical data and unstructured notes and predicts the individual likelihood of cachexia.